Correlation Between Bristol Myers and Structure Therapeutics
Can any of the company-specific risk be diversified away by investing in both Bristol Myers and Structure Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bristol Myers and Structure Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Bristol Myers Squibb and Structure Therapeutics American, you can compare the effects of market volatilities on Bristol Myers and Structure Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bristol Myers with a short position of Structure Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bristol Myers and Structure Therapeutics.
Diversification Opportunities for Bristol Myers and Structure Therapeutics
-0.51 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Bristol and Structure is -0.51. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and Structure Therapeutics America in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Structure Therapeutics and Bristol Myers is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bristol Myers Squibb are associated (or correlated) with Structure Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Structure Therapeutics has no effect on the direction of Bristol Myers i.e., Bristol Myers and Structure Therapeutics go up and down completely randomly.
Pair Corralation between Bristol Myers and Structure Therapeutics
Considering the 90-day investment horizon Bristol Myers Squibb is expected to generate 0.63 times more return on investment than Structure Therapeutics. However, Bristol Myers Squibb is 1.58 times less risky than Structure Therapeutics. It trades about 0.12 of its potential returns per unit of risk. Structure Therapeutics American is currently generating about -0.21 per unit of risk. If you would invest 5,577 in Bristol Myers Squibb on September 1, 2024 and sell it today you would earn a total of 345.00 from holding Bristol Myers Squibb or generate 6.19% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Bristol Myers Squibb vs. Structure Therapeutics America
Performance |
| Timeline |
| Bristol Myers Squibb |
| Structure Therapeutics |
Bristol Myers and Structure Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Bristol Myers and Structure Therapeutics
The main advantage of trading using opposite Bristol Myers and Structure Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bristol Myers position performs unexpectedly, Structure Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Structure Therapeutics will offset losses from the drop in Structure Therapeutics' long position.| Bristol Myers vs. Crinetics Pharmaceuticals | Bristol Myers vs. Enanta Pharmaceuticals | Bristol Myers vs. Amicus Therapeutics | Bristol Myers vs. Connect Biopharma Holdings |
| Structure Therapeutics vs. Day One Biopharmaceuticals | Structure Therapeutics vs. X4 Pharmaceuticals | Structure Therapeutics vs. Inozyme Pharma | Structure Therapeutics vs. Acumen Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Complementary Tools
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |